Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1997 Nov;35(11):2886–2893. doi: 10.1128/jcm.35.11.2886-2893.1997

Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma.

C C Ginocchio 1, X P Wang 1, M H Kaplan 1, G Mulligan 1, D Witt 1, J W Romano 1, M Cronin 1, R Carroll 1
PMCID: PMC230081  PMID: 9350753

Abstract

To define the optimal blood collection parameters for plasma human immunodeficiency virus type 1 (HIV-1) viral load testing, plasma HIV-1 RNA levels were quantitated with the NASBA HIV-1 RNA QT System from blood specimens that were collected, processed, and stored under a variety of conditions that might have affected HIV-1 RNA stability. We determined that when whole blood was processed within 2 h of specimen collection the levels of HIV-1 RNA detected in EDTA-, heparin-, and acid citrate dextrose (ACD)-anticoagulated plasma samples were comparable. The levels of HIV-1 RNA in serum specimens (mean = 4.126 log units) were significantly lower (P < 0.01) than the levels in corresponding plasma samples (mean = 4.501 log units). One cycle of freeze-thaw (-70 degrees C) did not significantly reduce the level of HIV-1 RNA detected in EDTA-, heparin-, or ACD-anticoagulated plasmas. The EDTA-anticoagulated plasmas showed the smallest decrease in HIV-1 RNA copies (0.050 log units). HIV-1 RNA levels decreased over a 6-month time period in serum as well as in EDTA-, ACD-, and heparin-anticoagulated plasmas stored at -70 degrees C. However, the only significant decreases were for serum (mean decrease = 0.317 log units) and heparin-anticoagulated samples (mean decrease = 0.384 log units). A comparison of the levels of HIV-1 RNA in cell-free plasma collected in VACUTAINER EDTA Plasma Preparation Tubes and in standard VACUTAINER EDTA tubes determined that HIV-1 RNA levels were stable for up to 30 h after collection when stored at either room temperature (mean standard deviation [SD] = +/- 0.101 log units) or at 4 degrees C (mean SD = +/- 0.102 log units) as cell-free plasma or as EDTA-anticoagulated whole blood (mean SD = +/- 0.109 log units). These data indicate that EDTA-anticoagulated plasma is the most suitable and stable matrix for HIV-1 RNA quantitation.

Full Text

The Full Text of this article is available as a PDF (170.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagnarelli P., Menzo S., Valenza A., Paolucci S., Petroni S., Scalise G., Sampaolesi R., Manzin A., Varaldo P. E., Clementi M. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol. 1995 Jan;33(1):16–23. doi: 10.1128/jcm.33.1.16-23.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Collier A. C., Coombs R. W., Fischl M. A., Skolnik P. R., Northfelt D., Boutin P., Hooper C. J., Kaplan L. D., Volberding P. A., Davis L. G. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15;119(8):786–793. doi: 10.7326/0003-4819-119-8-199310150-00003. [DOI] [PubMed] [Google Scholar]
  3. Coombs R. W. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS. Clin Lab Med. 1994 Jun;14(2):301–311. [PubMed] [Google Scholar]
  4. Coombs R. W., Henrard D. R., Mehaffey W. F., Gibson J., Eggert E., Quinn T. C., Phillips J. Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J Clin Microbiol. 1993 Aug;31(8):1980–1986. doi: 10.1128/jcm.31.8.1980-1986.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coombs R. W., Welles S. L., Hooper C., Reichelderfer P. S., D'Aquila R. T., Japour A. J., Johnson V. A., Kuritzkes D. R., Richman D. D., Kwok S. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct;174(4):704–712. doi: 10.1093/infdis/174.4.704. [DOI] [PubMed] [Google Scholar]
  6. Cunningham A. L., Dwyer D. E., Dowton D. N. Viral markers in HIV infection and AIDS. J Acquir Immune Defic Syndr. 1993;6 (Suppl 1):S32–S35. [PubMed] [Google Scholar]
  7. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  8. Hogervorst E., Jurriaans S., de Wolf F., van Wijk A., Wiersma A., Valk M., Roos M., van Gemen B., Coutinho R., Miedema F. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis. 1995 Apr;171(4):811–821. doi: 10.1093/infdis/171.4.811. [DOI] [PubMed] [Google Scholar]
  9. Holodniy M., Katzenstein D. A., Israelski D. M., Merigan T. C. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest. 1991 Nov;88(5):1755–1759. doi: 10.1172/JCI115494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Holodniy M., Katzenstein D., Winters M., Montoya J., Shafer R., Kozal M., Ragni M., Merigan T. C. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr. 1993 Apr;6(4):366–369. [PubMed] [Google Scholar]
  11. Holodniy M., Kim S., Katzenstein D., Konrad M., Groves E., Merigan T. C. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol. 1991 Apr;29(4):676–679. doi: 10.1128/jcm.29.4.676-679.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Holodniy M., Mole L., Yen-Lieberman B., Margolis D., Starkey C., Carroll R., Spahlinger T., Todd J., Jackson J. B. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol. 1995 Jun;33(6):1562–1566. doi: 10.1128/jcm.33.6.1562-1566.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jurriaans S., Van Gemen B., Weverling G. J., Van Strijp D., Nara P., Coutinho R., Koot M., Schuitemaker H., Goudsmit J. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology. 1994 Oct;204(1):223–233. doi: 10.1006/viro.1994.1526. [DOI] [PubMed] [Google Scholar]
  14. Klebanoff S. J., Coombs R. W. Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system. J Clin Invest. 1992 Jun;89(6):2014–2017. doi: 10.1172/JCI115810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lee T. H., Stromberg R. R., Henrard D., Busch M. P. Effect of platelet-associated virus on assays of HIV-1 in plasma. Science. 1993 Dec 3;262(5139):1585–1586. doi: 10.1126/science.8248811. [DOI] [PubMed] [Google Scholar]
  16. Mellors J. W., Kingsley L. A., Rinaldo C. R., Jr, Todd J. A., Hoo B. S., Kokka R. P., Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995 Apr 15;122(8):573–579. doi: 10.7326/0003-4819-122-8-199504150-00003. [DOI] [PubMed] [Google Scholar]
  17. Mole L., Margolis D., Carroll R., Todd J., Holodniy M. Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes. J Clin Microbiol. 1994 Sep;32(9):2212–2215. doi: 10.1128/jcm.32.9.2212-2215.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Moudgil T., Daar E. S. Infectious decay of human immunodeficiency virus type 1 in plasma. J Infect Dis. 1993 Jan;167(1):210–212. doi: 10.1093/infdis/167.1.210. [DOI] [PubMed] [Google Scholar]
  19. O'Brien W. A., Hartigan P. M., Martin D., Esinhart J., Hill A., Benoit S., Rubin M., Simberkoff M. S., Hamilton J. D. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996 Feb 15;334(7):426–431. doi: 10.1056/NEJM199602153340703. [DOI] [PubMed] [Google Scholar]
  20. O'Shea S., Rostron T., Mullen J. E., Banatvala J. E. Stability of infectious HIV in clinical samples and isolation from small volumes of whole blood. J Clin Pathol. 1994 Feb;47(2):152–154. doi: 10.1136/jcp.47.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pachl C., Todd J. A., Kern D. G., Sheridan P. J., Fong S. J., Stempien M., Hoo B., Besemer D., Yeghiazarian T., Irvine B. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 15;8(5):446–454. doi: 10.1097/00042560-199504120-00003. [DOI] [PubMed] [Google Scholar]
  22. Piatak M., Jr, Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993 Mar 19;259(5102):1749–1754. doi: 10.1126/science.8096089. [DOI] [PubMed] [Google Scholar]
  23. Vandamme A. M., Schmit J. C., Van Dooren S., Van Laethem K., Gobbers E., Kok W., Goubau P., Witvrouw M., Peetermans W., De Clercq E. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Oct 1;13(2):127–139. doi: 10.1097/00042560-199610010-00003. [DOI] [PubMed] [Google Scholar]
  24. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  25. van Gemen B., v d Wiel P., van Beuningen R., Sillekens P., Jurriaans S., Dries C., Schoones R., Kievits T. The one-tube quantitative HIV-1 RNA NASBA: precision, accuracy, and application. PCR Methods Appl. 1995 Feb;4(4):S177–S184. doi: 10.1101/gr.4.4.s177. [DOI] [PubMed] [Google Scholar]
  26. van Gemen B., van Beuningen R., Nabbe A., van Strijp D., Jurriaans S., Lens P., Kievits T. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods. 1994 Sep;49(2):157–167. doi: 10.1016/0166-0934(94)90040-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES